Pharsight

Xaracoll patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47826 INNOCOLL PHARMS Drug delivery device for providing local analgesia, local anesthesia or nerve blockage
May, 2029

(4 years from now)

US11746141 INNOCOLL PHARMS Modified collagen
Jan, 2033

(8 years from now)

Xaracoll is owned by Innocoll Pharms.

Xaracoll contains Bupivacaine Hydrochloride.

Xaracoll has a total of 2 drug patents out of which 0 drug patents have expired.

Xaracoll was authorised for market use on 28 August, 2020.

Xaracoll is available in implant;implantation dosage forms.

Xaracoll can be used as a method for inducing a post-surgical analgesia sparing effect by implanting at the surgical site a collagen sponge containing bupivacaine hcl which provides local anesthesia for up to 24 hours following implantation.

The generics of Xaracoll are possible to be released after 09 January, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 28, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using BUPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 August, 2020

Treatment: A method for inducing a post-surgical analgesia sparing effect by implanting at the surgical site a collagen sponge containing bupivacaine hcl which provides local anesthesia for up to 24 hours follow...

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

XARACOLL family patents

Family Patents